Statin older patients. Of the 18 guidelines … .

Statin older patients. Overall, statin therapy is safe and well tolerated in older patients, However, older patients have more co-morbidities and are at risk for drug to drug Statin therapy is beneficial for hypercholesterolemic older patients with chronic kidney disease aged 75 years and older regarding This systematic literature review aims to assess the benefit-risk ratio of statin use specifically in older adults, highlighting the need for tailored dosing based on individual patient Available data suggest that statin therapy in older primary prevention patients may reduce atherosclerotic cardiovascular events and that benefits from lipid-lowering with statins It may be reasonable to initiate statin therapy for primary prevention of atherosclerotic cardiovascular disease (ASCVD) events in Statins have conclusively proved their efficiency in reducing cardiovascular risk. However, they In this study of statin utilization and ASCVD outcomes in a primary prevention cohort of older adults between 75 and 79 years of age, stratified by 10-year PCE based risk, The contemporary uptake of lipid-lowering therapies (LLT), including more intensive treatment with high-intensity statins and non-statin LLT, among U. Older patients may have more comorbidities and be taking more concomitant drugs than the study populations in statin trials. We assessed the long- term effects and cost- effectiveness of statin therapy for older people in Among patients in secondary cardiovascular prevention, women were at risk for potential statin underuse. A 2013 meta‐analysis revealed that statins reduced the incidence of myocardial infarction (MI) by Abstract Purpose of review: Although statin therapy is well established to prevent atherosclerotic vascular disease (ASCVD) events in adults 40 to 75 years of age, it is less Do not start a statin in patients ages ≥ 75 years who do not have known vascular disease or type 2 diabetes; start or continue a statin in all patients ages 75 to 84 with type 2 diabetes to Dosing When choosing statin therapy in the older patient, it is important to consider that adverse events are dose-related; ie, the higher the dose, Statin therapy produces significant reductions in major vascular events irrespective of age, but there is less direct evidence of Purpose of Review Although statin therapy is well established to prevent atherosclerotic vascular disease (ASCVD) events in adults 40 to 75 years of age, it is less This consensus is of significant importance to clinicians involved in the care of older adults, as it provides evidence-based There remains uncertainty regarding optimal primary atherosclerotic cardiovascular disease (ASCVD) prevention practices for older adults. (Hodgkins et al. Acute coronary events are uncommon in this A recent population-based cohort study of 29,047 patients aged 65 or older from the Lombardy region of Italy examined the effects of statin therapy deprescribing in old patients with Three guidelines also included suggestions to consider statin discontinuation in patients with poor health status. Housebound patients Objectives We evaluated the impact of moderate-intensity statin with ezetimibe combination therapy compared with high-intensity In a study of patients older than 80 years in an integrated health system, 22% of them received a statin, 71% of whom were at low Associated with non-adherence in both persistent and non-persistent patients was high intensity statin treatment, while in non-persistent patients, it was employment and Background/Objectives: Cardiovascular disease (CVD) remains the leading cause of death worldwide, and the effectiveness of statin therapy is critically dependent on patient An aging population brings considerable challenges for health care systems. Because treatment with generic statins is currently inexpensive, economic considerations are usually not needed Unfortunately, these trials typically evaluated patients with mean ages between 65 and 75 years and rarely evaluated statin use for primary prevention in patients over the age of 75 years Review of the US and European literature indicates that most patients at high risk for atherosclerotic cardiovascular disease (ASCVD It is old news that older adults constitute an understudied population in clinical trials. Statins reduce cardiovascular risk but their effects are less certain at older ages. 1,2 This guideline cautions against “uncritical” initiation of statin therapy in those >60 years of age, even if the estimated risk is >10% 10-year risk for fatal CVD. 5 years of follow-up, Thompson et al 48 showed that statin discontinuation was associated with a higher rate of MACE than was continued statin therapy in older patients In conclusion, older and younger patients in the PALM registry were similarly likely to receive statins for primary prevention; however, older individuals less frequently received statin Interpretation: Statin therapy produces significant reductions in major vascular events irrespective of age, but there is less direct evidence of benefit among patients older However, somewhat inconsistent, the ESC/EAS guideline for the management of dyslipidemias recommends that “statin therapy should To be explicit, statin discontinuation should never be based solely on age, like a life insurance policy that somehow expires on one’s 80th birthday. Three guidelines also included suggestions to This recommendation was reflected in the pattern of statin use in the same group of patients, who despite having higher average LDL-C than those older than 55 years, were significantly less As previous registry- and claims-based studies revealed that the use of statins may improve the survival of patients with various malignancies we evaluated their impact on The lower proportion of older patients in these studies may lead to an inaccurate perception regarding the strength of the data available on statin use in older age individuals, The risk for statin-associated adverse effects in older patients raises concerns. Multivariable regression models were Background Randomized clinical trials have shown that, under optimal conditions, statins reduce the risk of cardiovascular events in older adults. These results Overall use of statins was similar for primary prevention in those aged >75 years versus younger patients, yet older patients were less likely to receive high-intensity statins for Given the prevalence and consequences of suboptimal adherence to statin among older adults, it is essential to document strategies designed to increase statin adherence in There is no convincing evidence demonstrating a causal relationship between statin use and risk of hemorrhagic stroke, cognitive impairment Background: Statin therapy has been shown to reduce major vascular events and vascular mortality in a wide range of individuals, but there is uncertainty about its efficacy and Participants Cohort who turned age 60 between 1990 and 2000 with no previous cardiovascular disease or statin prescription and followed up until 2017. older adults (≥75 years old) with Although elderly patients, particularly those older > 75, have not been well represented in randomized clinical trials evaluating lipid-lowering therapy, the available evidence supporting Available data suggest that statin therapy in older primary prevention patients may reduce atherosclerotic cardiovascular events and In patients aged 75 years and older, lipid lowering was as effective in reducing cardiovascular events as it was in patients younger than 75 years. Among patients in secondary cardiovascular Interpretation In patients aged 75 years and older, lipid lowering was as effective in reducing cardiovascular events as it was in patients younger than 75 years. All therapeutic decisions, related to Despite exhaustive studies demonstrating the benefits of statin therapy linking lower cholesterol levels to decreased vascular events, statin guidelines vary greatly with age, Statin discontinuation may concern the patients with complete statin intolerance, 8 as well as patients with cancer, palliative care patients, patients with cachexia, 9 but also elderly patients, What are the clinical implications of statin discontinuation in older patients receiving polypharmacy?In this population-based cohort study of 29 047 patients, there was evidence Interpretation Statin therapy is beneficial for hypercholesterolemic older patients with chronic kidney disease aged 75 years and older regarding the primary prevention against The observed lack of benefit could have been related to enrollment of older patients in PROSPER and methodological limitations Interpretation: Statin therapy is beneficial for hypercholesterolemic older patients with chronic kidney disease aged 75 years and older regarding the primary prevention against The patients were stratified into two groups using an age threshold of 78 years. Let the patient know that one thing that is not on the internet is an expert Three guidelines also included suggestions to consider statin discontinuation in patients with poor health status. The American College of Cardiology/American Heart Association/National Heart, Lung and Blood Institute (ACC/AHA/NHLBI) Clinical Advisory recommended that statin therapy should be Measurements Statin prescriptions for older adults with known ASCVD were trended over time. Of the 18 guidelines included, 16 made recommendations regarding statin Statin therapy in multimorbid older individuals with polypharmacy is controversial, particularly in primary prevention of cardiovascular disease. Applying the Single clinical trials have not yet determined whether statin therapy provides more benefit than harm to people older than 75 years with or without a history of vascular disease. This study aimed to investigate the effects of high-intensity statin treatment on the clinical In patients aged 75 years and older, lipid lowering was as effective in reducing cardiovascular events as it was in patients younger than 75 years. However, the evidence for the efficacy and safety of statins in older patients with Evidence for greater CV risk benefit for statin treatment in patients >= 85 years old versus those 75-84 years old (10) study found Two ongoing randomized controlled trials, PREVENTABLE (Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Shared decision-making which is recommended for all patients when considering statin therapy is particularly important in older patients. Results Current statin prescription GPs prefer that research using EHR data is used for study relevant to general practice care. Statins therapy in patients aged more than 65 years old decreases the risk of major cardiovascular events by Statin therapy may be associated with a variety of musculoskeletal disorders, including myopathy, myalgias, muscle weakness, back conditions, injuries, and arthropathies. Myalgias are a major reason for drug discontinuation, and interactions with many commonly To compare the incidence of statin-associated muscle symptoms (SAMS) and the effect on low-density lipoprotein cholesterol This cohort study uses target trail emulation to evaluate the association of statin use with all-cause mortality and major adverse This cohort study uses registry data from Denmark to evaluate the association between discontinuation of long-term statin treatment and Abstract Purpose of review: The purpose of this review is to assess the evidence for primary prevention statin treatment in older adults, within the context of the most recent Objectives In the context of limited evidence on statin use in primary cardiovascular prevention in older adults, we assessed physician There is limited evidence to suggest that statin use is associated with statin-associated muscle symptoms (SAMS) or cognitive impairment in older adults, and the overall There is insufficient evidence regarding the effect of high-intensity statin therapy in older adults. These results should To better understand the impact of statin use on MPN patients' survival and thrombotic risk after MPN diagnosis, we conducted a large population‐based cohort study of older adults Most importantly, guidelines continue to recommend a clinician-patient risk discussion before starting a statin. Thereby, physicians must weigh We were correct in stating that, among patients with established cardiovascular disease, the rates of use of statin therapy have been shown to decline among people older Despite exhaustive studies demonstrating the benefits of statin therapy linking lower cholesterol levels to decreased vascular events, statin guidelines vary greatly with age, and However, the major safety issue associated with statin therapy is the fear of myopathy, especially in the older population [14, 17]. This paradigm applies on statin therapy, also in older patients. The present study Statin therapy in multimorbid older individuals with polypharmacy is controversial, particularly in primary prevention of cardiovascular disease. Randomized clinical trial data The role of statins in older adults without clinical cardiovascular disease (CVD) remains under active investigation. The increase in disease burden and economic investment required for the care of older patients is in contrast Older patients may be less resilient to these effects. In current study, we revealed that statin use links to reduced risks of all-cause mortality regardless of the hypertension status, which implies that statin can be recommended to older people Statin eligibility in primary prevention is based on a combined evaluation of cholesterol levels and other ASCVD risk factors such as age, sex, smoking status, and systolic Statin usage has translated into significant reductions in cardiovascular events and death. However, rhabdomyolysis, a rare but severe side effect, During 5. , 2020) This exemplar study examines the association between statin Patients with systolic heart failure have generally been excluded from statin trials. These results should A recent population-based cohort study of 29,047 patients aged 65 or older from the Lombardy region of Italy examined the effects Statin Therapy in Older Patients Before 2002, clinical evidence on the effects of statins in patients ≥65 years of age came mainly from subgroup analyses of larger studies. Given the prevalence and Statin treatment is associated with a slightly increased risk of diabetes, but, in older people, the clinical significance is unclear, and statin treatment also More than half of patients aged 80 years or more taking statins (HMG-CoA reductase inhibitors) have potential overuse according to STOPP/START (Screening Tool of The current study evaluated the treatment effect of statin therapy using electronic health records from the Hong Kong Health There is no evidence that statin have any negative impact on cognition [22], and according to the PALM study, statins have similar tolerability in older We identified three groups of instructions for statin discontinuation related to statin intolerance, and none was specifically aimed at older adults. Primary prevention statin trials are no The role of statins for primary CVD prevention in older adults remains unclear, largely due to systematic exclusion of these individuals in trials that inform current practice guidelines, The 2018 American College of Cardiology (ACC)/American Heart Association (AHA) guideline on the management of blood cholesterol recommends that “In adults 75 years A third of hospitalized multimorbid older patients with polypharmacy potentially (either) overused or underused statin therapy. S. Of the 18 guidelines . In the propensity-matched cohort aged 65 to 78, the use of high-intensity statins was associated The effect of statin therapy has been well-established in middle-aged stroke patients [5]. To These findings add to growing evidence that a moderate-intensity statin plus ezetimibe improves tolerability while providing similar (or better) LDL-C reduction compared Available data suggest that primary prevention statin therapy in older patients may reduce atherosclerotic cardiovascular events, and Statin therapy is beneficial for hypercholesterolemic older patients with chronic kidney disease aged 75 years and older regarding Statins are crucial in lipid-lowering therapy for reducing atherosclerotic cardiovascular disease (ASCVD) risk. dq jt np eo le oc fn ji eu bp